ALACHUA, FL --(Marketwired - May 05, 2015) - AxoGen, Inc. (
"The market's continued adoption of our proprietary portfolio of nerve repair products -- Avance ® Nerve Graft, AxoGuard ® Nerve Connector and AxoGuard ® Nerve Protector -- and our solid sales execution delivered another record quarter with revenue increasing 58% year-over-year," commented Karen Zaderej, Chief Executive Officer. "Despite some negative effects of severe weather in January and February, this quarter continues our strong growth momentum of the last 2 years and is directly related to our focus on executing our sales and marketing strategy."
2015 First Quarter Financial Results
For the first quarter ended March 31, 2015, revenue totaled $4.95 million, a 58% increase compared to $3.14 million in the prior year first quarter. The Company reported gross margin expanded to 80.1% compared to 77.7% in the first quarter ended March 31, 2014. Net loss was $3.6 million, or $0.16 per share compared to a net loss of $4.2 million, or $0.24 per share in the year-ago first quarter. The weighted average common shares outstanding for the 2015 first quarter were approximately 22.5 million shares compared to 17.4 million shares in the 2014 first quarter.
As of March 31, 2015, cash and cash equivalents totaled $19.3 million which includes $13.6 million of net proceeds related to the public common stock offering in February.
2015 Guidance
Given the market's increasing awareness of AxoGen's product portfolio and the Company's plans to expand its sales footprint and sales pipeline, AxoGen is reaffirming its 2015 full year revenue outlook of at least $24 million with annual gross margin in the mid to high 70% range.
Conference Call The Company will host a conference call and webcast for the investment community following the release at 4:30 PM ET. Investors interested in participating by phone are invited to call toll free at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. Those interested in joining via the webcast, should visit http://axogeninc.equisolvewebcast.com/q1-2015 .
Following the conference call, a replay will be available on the Company's website at www.AxoGenInc.com , under 'Investors.'
About AxoGen, Inc.
AxoGen (
Avance ® Nerve Graft is processed in the United States by AxoGen. AxoGuard ® Nerve Connector and AxoGuard ® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.
Cautionary Statement Concerning Forward-Looking Statements This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the closing of the over-allotment option and the AxoGen's proposed use of proceeds. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development, product potential, or the intended use of proceeds from the offering. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
| AXOGEN, INC. | ||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| March 31, | ||||||||||
| 2015 | December 31, | |||||||||
| (unaudited) | 2014 | |||||||||
| Assets | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 19,255,725 | $ | 8,215,791 | ||||||
| Accounts receivable | 3,161,588 | 2,872,308 | ||||||||
| Inventory | 3,337,898 | 3,213,620 | ||||||||
| Prepaid expenses and other | 259,948 | 109,369 | ||||||||
| Total current assets | 26,015,159 | 14,411,088 | ||||||||
| Property and equipment, net | 583,420 | 619,028 | ||||||||
| Intangible assets | 597,453 | 577,174 | ||||||||
| Deferred financing costs | 939,894 | 793,499 | ||||||||
| $ | 28,135,926 | $ | 16,400,789 | |||||||
| Liabilities and Shareholders' Equity (Deficit) | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable and accrued expenses | $ | 3,423,272 | $ | 2,431,194 | ||||||
| Current Deferred Revenue | 14,118 | 14,118 | ||||||||
| Total current liabilities | 3,437,390 | 2,445,312 | ||||||||
| Note Payable - Revenue Interest Purchase Agreement | 25,269,050 | 25,085,777 | ||||||||
| Long Term Deferred Revenue | 109,984 | 115,380 | ||||||||
| Total liabilities | 28,816,424 | 27,646,469 | ||||||||
| Shareholders' equity (deficit): | ||||||||||
| Common stock, $.01 par value; 50,000,000 shares authorized; 24,926,014 and 19,488,814 shares issued and outstanding | 249,260 | 194,888 | ||||||||
| Additional paid-in capital | 92,761,697 | 78,675,686 | ||||||||
| Accumulated deficit | (93,691,455 | ) | (90,116,254 | ) | ||||||
| Total shareholders' equity (deficit) | (680,498 | ) | (11,245,680 | ) | ||||||
| $ | 28,135,926 | $ | 16,400,789 | |||||||
| AXOGEN, INC. | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||
| Three Months ended March 31, 2015 and 2014 | ||||||||||
| (unaudited) | ||||||||||
| 2015 | 2014 | |||||||||
| Revenues | $ | 4,951,316 | $ | 3,138,256 | ||||||
| Cost of goods sold | 982,881 | 701,300 | ||||||||
| Gross profit | 3,968,435 | 2,436,956 | ||||||||
| Costs and expenses: | ||||||||||
| Sales and marketing | 3,932,522 | 2,720,707 | ||||||||
| Research and development | 671,036 | 812,615 | ||||||||
| General and administrative | 1,908,581 | 1,894,776 | ||||||||
| Total costs and expenses | 6,512,139 | 5,428,098 | ||||||||
| Loss from operations | (2,543,704 | ) | (2,991,142 | ) | ||||||
| Other expense: | ||||||||||
| Interest expense | (994,748 | ) | (1,191,317 | ) | ||||||
| Interest expense - deferred financing costs | (33,746 | ) | (51,216 | ) | ||||||
| Other expense | (3,003 | ) | (5,889 | ) | ||||||
| Total other expense | (1,031,497 | ) | (1,248,422 | ) | ||||||
| Net loss | $ | (3,575,201 | ) | $ | (4,239,564 | ) | ||||
| Weighted Average Common Shares outstanding - basic and diluted | 22,517,361 | 17,383,786 | ||||||||
| Loss Per Common share - basic and diluted | $ | (0.16 | ) | $ | (0.24 | ) | ||||
| AXOGEN, INC. | ||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||
| Three Months ended March 31, 2015 and 2014 | ||||||||||
| (unaudited) | ||||||||||
| 2015 | 2014 | |||||||||
| Cash flows from operating activities: | ||||||||||
| Net loss | $ | (3,575,201 | ) | $ | (4,239,564 | ) | ||||
| Adjustments to reconcile net loss to net cash used for operating activities: | ||||||||||
| Depreciation | 41,898 | 33,944 | ||||||||
| Amortization of intangible assets | 11,772 | 10,955 | ||||||||
| Amortization of deferred financing costs | 33,746 | 51,216 | ||||||||
| Share-based compensation | 368,249 | 257,542 | ||||||||
| Stock grants | -- | 60,125 | ||||||||
| Interest added to note payable | 183,273 | 891,845 | ||||||||
| Change in assets and liabilities: | ||||||||||
| Accounts receivable | (289,280 | ) | (71,458 | ) | ||||||
| Inventory | (124,278 | ) | (67,661 | ) | ||||||
| Prepaid expenses and other | (150,579 | ) | 101,230 | |||||||
| Accounts payable and accrued expenses | 992,078 | (175,196 | ) | |||||||
| Deferred revenue | (5,396 | ) | (3,571 | ) | ||||||
| Net cash used for operating activities | (2,513,718 | ) | (3,150,593 | ) | ||||||
| Cash flows from investing activities: | ||||||||||
| Purchase of property and equipment | (6,288 | ) | (195,482 | ) | ||||||
| Acquisition of intangible assets | (32,051 | ) | (8,346 | ) | ||||||
| Net cash used for investing activities | (38,339 | ) | (203,828 | ) | ||||||
| Cash flows from financing activities: | ||||||||||
| Proceeds from exercise of stock options | -- | 92,424 | ||||||||
| Proceeds from issuance of common stock | 13,772,133 | -- | ||||||||
| Debt issuance costs | (180,142 | ) | -- | |||||||
| Net cash provided by financing activities | 13,591,991 | 92,424 | ||||||||
| Net increase/(decrease) in cash and cash equivalents | 11,039,934 | (3,261,997 | ) | |||||||
| Cash and cash equivalents, beginning of year | 8,215,791 | 20,069,750 | ||||||||
| Cash and cash equivalents, end of period | $ | 19,255,725 | $ | 16,807,753 | ||||||
| Supplemental disclosures of cash flow activity: | ||||||||||
| Cash paid for interest | $ | 803,607 | $ | 303,919 | ||||||
Contact: AxoGen, Inc. Lee Robert "Bob" Johnston Chief Financial Officer 386.462.6856 InvestorRelations@AxoGenInc.com EVC Group Michael Polyviou 212.850.6020 mpolyviou@evcgroup.com